Adaptimmune Therapeutics (FRA:473A) 3-Year Revenue Growth Rate : 120.50% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics 3-Year Revenue Growth Rate?

Adaptimmune Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was €0.02.

During the past 12 months, Adaptimmune Therapeutics's average Revenue per Share Growth Rate was -80.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 120.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of Adaptimmune Therapeutics was 499.10% per year. The lowest was -62.00% per year. And the median was 30.30% per year.

Competitive Comparison of Adaptimmune Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Adaptimmune Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's 3-Year Revenue Growth Rate falls into.

Adaptimmune Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Adaptimmune Therapeutics (FRA:473A) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Adaptimmune Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics (FRA:473A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (FRA:473A) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ADAP:USA

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

Adaptimmune Therapeutics (FRA:473A) Headlines

No Headlines